Unusual 11 Mid-Day Movers 12/09: (BCSI) (FLOW) (DMND) (MNI) Higher; (CTIC) (PCYC) (FURX) Lower
Up)
Blue Coat (Nasdaq: BCSI) 44.2% HIGHER; holders to get $25.81/share in cash from PE firm Thoma Bravo.
Flow International Corp (NASDAQ: FLOW) 43% HIGHER; reported Q2 EPS of $0.06, $0.05 better than the analyst estimate of $0.01. Revenue for the quarter came in at $64.5 million versus the consensus estimate of $60.42 million.
Diamond Foods (Nasdaq: DMND) 43% HIGHER; a KeyBanc analyst issued a research note this morning suggesting a probe of Diamond Foods will show payments were properly accounted for. Click here to see the full report.
McClatchy (NYSE: MNI) 29.7% HIGHER; continuing to move higher following a 62 percent surge on Wednesday amid improved ad revs and thus strong FY12 guidance. The stock sold off by nearly 10 percent yesterday as traders took profits.
SIGA Technologies (Nasdaq: SIGA) 29.4% HIGHER; bouncing over the $2 level today.
Cooper Cos. (NYSE: COO) 19% HIGHER; reported Q4 EPS of $1.46, $0.24 better than the analyst estimate of $1.22. Revenue for the quarter came in at $360.9 million versus the consensus estimate of $356.93 million. Sees FY2012 EPS of $4.80-$5.00, versus the consensus of $4.66. Sees FY2012 revenue of $1.39-$1.44 billion, versus the consensus of $1.42 billion.
Cell Therapeutics, Inc. (Nasdaq: CTIC) 14.5% LOWER; has entered into an agreement to sell, subject to customary closing conditions, $20 million of shares of its Series 14 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to two institutional investors. Each share of Series 14 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 870 shares of common stock at a conversion price of $1.15 per share of common stock, for a total of approximately 17,391,304 shares of common stock.
Pharmacyclics, Inc. (Nasdaq: PCYC) 14.4% LOWER; has entered into a worldwide collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ), to develop and commercialize PCI-32765, a novel, oral, first-in-class Bruton's tyrosine kinase (Btk) inhibitor being developed for the treatment of Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma, all of which are considered hematological malignancies. PCI-32765 was developed by Pharmacyclics and is currently in Phase II clinical trials. Under the terms of the agreement, Pharmacyclics will receive an upfront payment of $150 million. In addition, Pharmacyclics will receive up to an additional $825 million in development and regulatory milestone payments, based upon continued development, regulatory progress and approval of the product, for total potential upfront and milestone payments of $975 million. The stock was also downgraded at RBC and Global Hunter this morning.
Furiex Pharmaceuticals (Nasdaq: FURX) 8.8% LOWER; on December 8th, the announced top-line results from the Phase II trial of the investigational drug PPD-10558 in patients with statin-associated myalgia. PPD-10558 did not meet its primary efficacy endpoint in this randomized, double-blind, proof-of-concept study. Patients did not report any significant differences in muscle symptoms, nor did they drop out due to statin-associated myalgia in significantly different percentages, among the three regimens. As expected, however, PPD-10558, a novel statin, did significantly lower LDL-cholesterol compared with placebo, and the compound also had a favorable safety profile.
E-Commerce China Dangdang (Nasdaq: DANG) 8.3% LOWER; investors are taking profits on shares of DANG today following a 22% increase yesterday.
OYO Geospace Corp (Nasdaq: OYOG) 7.8% LOWER; reported Q4 EPS of $0.56, $0.69 worse than the analyst estimate of $1.25. Revenue for the quarter came in at $32.81 million versus the consensus estimate of $41.88 million.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Flow International Corp (NASDAQ: FLOW) 43% HIGHER; reported Q2 EPS of $0.06, $0.05 better than the analyst estimate of $0.01. Revenue for the quarter came in at $64.5 million versus the consensus estimate of $60.42 million.
Diamond Foods (Nasdaq: DMND) 43% HIGHER; a KeyBanc analyst issued a research note this morning suggesting a probe of Diamond Foods will show payments were properly accounted for. Click here to see the full report.
McClatchy (NYSE: MNI) 29.7% HIGHER; continuing to move higher following a 62 percent surge on Wednesday amid improved ad revs and thus strong FY12 guidance. The stock sold off by nearly 10 percent yesterday as traders took profits.
SIGA Technologies (Nasdaq: SIGA) 29.4% HIGHER; bouncing over the $2 level today.
Cooper Cos. (NYSE: COO) 19% HIGHER; reported Q4 EPS of $1.46, $0.24 better than the analyst estimate of $1.22. Revenue for the quarter came in at $360.9 million versus the consensus estimate of $356.93 million. Sees FY2012 EPS of $4.80-$5.00, versus the consensus of $4.66. Sees FY2012 revenue of $1.39-$1.44 billion, versus the consensus of $1.42 billion.
Cell Therapeutics, Inc. (Nasdaq: CTIC) 14.5% LOWER; has entered into an agreement to sell, subject to customary closing conditions, $20 million of shares of its Series 14 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to two institutional investors. Each share of Series 14 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 870 shares of common stock at a conversion price of $1.15 per share of common stock, for a total of approximately 17,391,304 shares of common stock.
Pharmacyclics, Inc. (Nasdaq: PCYC) 14.4% LOWER; has entered into a worldwide collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ), to develop and commercialize PCI-32765, a novel, oral, first-in-class Bruton's tyrosine kinase (Btk) inhibitor being developed for the treatment of Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma, all of which are considered hematological malignancies. PCI-32765 was developed by Pharmacyclics and is currently in Phase II clinical trials. Under the terms of the agreement, Pharmacyclics will receive an upfront payment of $150 million. In addition, Pharmacyclics will receive up to an additional $825 million in development and regulatory milestone payments, based upon continued development, regulatory progress and approval of the product, for total potential upfront and milestone payments of $975 million. The stock was also downgraded at RBC and Global Hunter this morning.
Furiex Pharmaceuticals (Nasdaq: FURX) 8.8% LOWER; on December 8th, the announced top-line results from the Phase II trial of the investigational drug PPD-10558 in patients with statin-associated myalgia. PPD-10558 did not meet its primary efficacy endpoint in this randomized, double-blind, proof-of-concept study. Patients did not report any significant differences in muscle symptoms, nor did they drop out due to statin-associated myalgia in significantly different percentages, among the three regimens. As expected, however, PPD-10558, a novel statin, did significantly lower LDL-cholesterol compared with placebo, and the compound also had a favorable safety profile.
E-Commerce China Dangdang (Nasdaq: DANG) 8.3% LOWER; investors are taking profits on shares of DANG today following a 22% increase yesterday.
OYO Geospace Corp (Nasdaq: OYOG) 7.8% LOWER; reported Q4 EPS of $0.56, $0.69 worse than the analyst estimate of $1.25. Revenue for the quarter came in at $32.81 million versus the consensus estimate of $41.88 million.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Notable ETF Movers of the Day 05/25: (EWZ) (GLD) Higher; (VXX) (UNG) Lower
- Pre-Open Movers 5/24: (P) (HPQ) (PVH) Higher; (NTAP) (MTGE) (TIF) Lower (more...)
- Notable 52-Week Highs and Lows of the Day 05/24: (LCC) (PETM) (DUK) High; (NTAP) (RIMM) (CPRX) Low
Create E-mail Alert Related Categories
Special ReportsRelated Entities
KeyBanc, Unusual 11 Mid-Day MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
